目的：探讨中国儿童神经母细胞瘤（NB）中间变性淋巴瘤激酶（ALK）基因的突变情况。方法：从22例石蜡包埋的NB肿瘤组织中提取基因组DNA，通过PCR-DNA直接测序技术分析儿童NB肿瘤组织中ALK突变热点区域第20~26号外显子的突变情况。结果：22 例儿童NB中，有10例（46%）在ALK第21号外显子上存在已知同义突变C3375A（Gly1125Gly），等位基因频率为27%；1例（5%）在ALK第23号外显子上发现一个新的同义突变C3586T（Leu1196Leu）。ALK突变C3375A的发生频率在NB患儿的年龄、性别、肿瘤分化程度和是否转移方面差异无统计学意义（P＞0.05）。在其他5个ALK外显子中未发现突变。结论：采用PCR-DNA测序技术发现了ALK一个新的同义突变C3586T，并证实了儿童ALK存在已知突变C3375A，其发生率不受NB患儿临床特征的影响。
Abstract
OBJECTIVE: To investigate mutations of anaplastic lymphoma kinase (ALK) in Chinese children with neuroblastoma (NB). METHODS: Genomic DNA was extracted from 22 cases of paraffin-embedding NB tumor tissues. Gene mutations in the exons 20-26 which were mutational hotspots of ALK were analyzed by PCR-DNA direct sequencing. RESULTS: A novel synonymous mutation C3586T (Leu1196Leu) and a known synonymous mutation C3375A (Gly1125Gly) were found and located at exon 23 and exon 21 of ALK respectively. There were 10 cases (46%) of known synonymous mutation C3375A in 22 cases of NB. The C3375A allelic frequency was 27%. No statistically significant correlation was found between mutation C3375A and clinical parameters of NB such as age, sex, metastasis and tumor differentiation. Mutation was not found in the other 5 exons. CONCLUSIONS: A novel ALK gene synonymous mutation C3586T was identified using PCR-DNA sequencing. A known mutation C3375A in ALK was successfully identified in children, and its incidence is not influenced by the clinical features of childhood NB.
关键词
神经母细胞瘤 /
间变性淋巴瘤激酶 /
基因突变 /
儿童
Key words
Neuroblastoma /
Anaplastic lymphoma kinase /
Gene mutation /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］杨春兰，岳丽杰.间变性淋巴瘤激酶与神经母细胞瘤关系的研究进展［J］.中国肿瘤临床，2012，39（11）：813-816.
［2］朱琪琦，刘英，冯晨，唐锁勤. 神经母细胞瘤远期复发临床研究［J］.中国当代儿科杂志，2010，12（12）：995-997.
［3］Azarova AM, Gautam G, George RE. Emerging importance of ALK in neuroblastoma［J］. Semin Cancer Biol, 2011, 21(4): 267-275.
［4］Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of ALK kinase in neuroblastoma［J］. Nature, 2008, 455(7215): 971-974.
［5］George RE, Sanda T, Hanna M, Fr-hling S, Luther W 2nd, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastom［J］. Nature, 2008, 455(7215): 975-978.
［6］Carén H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumors［J］. Biochem J, 2008, 416(2): 153-159.
［7］张锦华，王维林，陈鸿骏.小儿神经母细胞瘤［M］.北京：人民卫生出版社，2009：89-92.
［8］Li R, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy［J］. Med Res Rev, 2008, 28(3): 372-412.
［9］Pearson R, Kolesar JM. Targeted therapy for NSCLC: ALK inhibition［J］. J Oncol Pharm Pract, 2012, 18(2): 271-274.
［10］Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma［J］. Nature, 2008, 455(7215): 967-970.
［11］Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene［J］. Nature, 2008, 455(7215): 930-935.
［12］Kwon MJ, Choi YL, Sung KW, Kang SY, Park SM, Choi SY, et al. Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors［J］. PatholRes Pract, 2011, 207(10): 634-639.
［13］Bagci O, Tumer S, Olgun N, Altungoz O. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors［J］. Cancer Lett, 2012, 317(1): 72-77.
［14］Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients［J］. Cancer Res, 2009, 69（18）: 7338-7346.
PDF(1141 KB)
